Search research articles
Contact Us
Filters
Showing results (91-100 of 130) with videos related to
Page
of 13
Sort By:
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance
|
October 23, 2024
Cardiac diffusion-weighted and tensor imaging: A consensus statement from the special interest group of the Society for Cardiovascular Magnetic Resonance
Erica Dall'Armellina, Daniel B Ennis, Leon Axel, et al.
JCO Precision Oncology
|
September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers
Scooter Willis, Yuliang Sun, Mark Abramovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Transfusion
|
July 13, 2020
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Francine M Foss, Xin Victoria Wang, Selina M Luger, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Blood Advances
|
August 20, 2024
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 130) with videos related to
Sort By:
Page
of 13
Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance
|
October 23, 2024
Cardiac diffusion-weighted and tensor imaging: A consensus statement from the special interest group of the Society for Cardiovascular Magnetic Resonance
Erica Dall'Armellina, Daniel B Ennis, Leon Axel, et al.
JCO Precision Oncology
|
September 11, 2020
High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers
Scooter Willis, Yuliang Sun, Mark Abramovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 27, 2025
Ipatasertib in Patients with Tumors with AKT Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1K
Carolyn K McCourt, Zihan Wei, Kevin Kalinsky, et al.
Transfusion
|
July 13, 2020
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902
Francine M Foss, Xin Victoria Wang, Selina M Luger, et al.
JCO Precision Oncology
|
February 20, 2026
Larotrectinib in Patients With Tumors With <i>NTRK</i> Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-Z1E
Neal Akhave, Zihe Song, David S Hong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 8, 2022
Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Senthil Damodaran, Fengmin Zhao, Dustin A Deming, et al.
JCO Precision Oncology
|
December 12, 2024
Phase II Study of Sunitinib in Tumors With <i>c-KIT</i> Mutations: Results From the NCI MATCH ECOG-ACRIN Trial (EAY131) Subprotocol V
Lilian T Gien, Zihe Song, Andrew Poklepovic, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
JCO Precision Oncology
|
January 14, 2026
Phase II Study of Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i><sup><i>V600E</i></sup> Mutations: Updated Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol H
April K S Salama, Victoria Wang, Erin R Macrae, et al.
Blood Advances
|
August 20, 2024
Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, et al.
Page
of 13